Prognostic value of delayed gadolinium enhancement MRI in patients with ischemic cardiomyopathy

Connecticut Medicine

Volumn 73, Issue 4, 2009, Pages 197-203

  Marcu, Constantin B ^a,c   Versteeg, Kathelijn S ^b   Beek, Aernout M ^b   Van Rossum, Albert C ^b  

^a Hospital of Saint Raphael   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL OF SAINT RAPHAEL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

AGED; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; MALE; METHODOLOGY; MIDDLE AGED; MITRAL VALVE REGURGITATION; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIOGRAPHY;

AGED; CONTRAST MEDIA; CORONARY ARTERY DISEASE; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PROGNOSIS; RADIOGRAPHIC IMAGE ENHANCEMENT; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 66349137986     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Heart disease and stroke statistics-2006 update: A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2006; 113:85-151.
2. Taylor G, Humphries J, Mellits E, et al: Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction. Circulation 1980; 62:960-70.
3. Mock MB, Ringqvist I, Fisher LD,et al Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982; 66:562-8.
4. Kim RJ, Shah DJ Judd RM: Howwe perform delayed enhancement imaging.J Cardiovasc Magn Reson 2003; 5:505-14.
5. Kim R, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl JMed '2000; 343(20):1445-53.
6. Thomson LE, Kim RJ Judd RM: Magnetic resonance imaging for the assessment of myocardial viability. J Magn Reson Imaging 2004; 19:771-88.
7. Marcu CB, Beek Am, van Rossum AC: Clinical applications of cardiovascular magnetic resonance imaging. CMAJ 2006; 175:911-17.
8. Marcu CB, Nijveldt R, Beek AM, van Rossum AC: Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease. Heart Lung Circ 2007; 16(2):70-8.
9. Cerqueira M, Weissman N, Dilsizian V, et al: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. Circulation 2002; 105:539-42.
10. AHA Science Advisory: Assessment of functional capacity in clinical and research applications. Circulation 2000; 102:1591-7.
11. Kubo S, Schulman S, Starling R,et al: Development and validation of a patient questionnaire to determine New York Heart Association classification.J Card Fail 2004; 10:228-35.
12. Di Carli MF, Davidson M, Little R, et al: Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994; 73:527-33.
13. Eitzman D, al Aouar Z, Kanter HL, et al: Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography.J Am Coll Cardiol 1992; 20:559-65.
14. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE: Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002; 39:1151-8.
15. Kuhl HP, Beek AM, van der Weerdt AP, et al: Myocardial viability in chronic ischemic heart disease: Comparison of contrast-enhanced magnetic resonance imaging with (18) F-fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2003; 41:1341-8.
16. Wagner A,Mahrholdt H,HollyTA,et al: Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study. Lancet 2003; 361(9355):374-9.
17. Shan K, Constantine G, Sivananthan M, Flamm SD: Role of cardiac magnetic resonance imaging in the assessment of myocardial viability. Circulation 2004; 109:1328-34.
18. Salukhe T, Henein M, Sutton R: Ischemic mitral regurgitation and its related risk after myocardial infarction. Circulation 2005; 111:254-6.
19. Tcheng JE, Jackman JD Jr, Nelson CL, et al: Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. Ann Intern Med 1992; 117:18-24.
20. Lehman KG, Francis CK, Dodge HT: Mitral regurgitation in early myocardial infarction. Incidence, clinical detection, and prognostic implications. TIMI Study Group. Ann Intern Med 1992; 117:10-17.
21. Lamas GA, Mitchel GF, Flaker GC, et al: Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and ventricular enlargement investigators. Circulation 1997; 96:827-33.
22. Feinberg MS.Schwammenthal E, Shlizerman L,et al: Prognostic significance of mild mitral regurgitation by color Doppler echocardiography in acute myocardial infarction.Am J Cardiol 2000; 86:903-7.
23. Grigioni F,Enriquez-Sarano M, Zehr KJ,et al: Ischemic mitral regurgitation: Long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001; 103:1759-64.
24. Bursi F, Enriquez-Sarano M, Nkomo VT, et al: Heart failure and death after myocardial infarction in the community: The emerging role of mitral regurgitation. Circulation 2005; 111:295-301.
25. Bello D, Shah DJ, Farah GM, et al: Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodelling in patients with heart failure undergoing ß-blocker therapy. Circulation 2003; 108:1945-53.
26. Bellenger NG, Rajappan K, Rahman SL, et al: Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: A cardiovascular magnetic resonance study. Heart 2004; 90:760-4.
27. Assomul RG,Prasad SK,Lyne J,etal:Cardiovascularmagnetic resonance, fibrosis and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48:1977-85.